Latest Genmab Stories
Focusing development on rare autoimmune disorder IgG4-related disease (IgG4-RD) MONROVIA, Calif., Oct. 28, 2014 /PRNewswire/ -- Xencor, Inc.
New cutting-edge report “Global Cancer Monoclonal Antibodies Market & Pipeline Insight” worked out by Kuick Research is now available at MarketPublishers.com. London,
COPENHAGEN, Denmark, Aug.
DUBLIN, July 28, 2014 /PRNewswire/ -- Research and Markets has announced the
LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL), ibrutinib significantly outperformed ofatumumab as a second-line therapy.
LONDON, April 17, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) and Genmab A/S (OMX: GEN) announced today that the U.S.
TUCSON, Ariz., April 3, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.